Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
In situ expansion and reprogramming of Kupffer cells elicit potent tumoricidal immunity against liver metastasis
Wei Liu, … , Lu Li, Zhutian Zeng
Wei Liu, … , Lu Li, Zhutian Zeng
Published February 23, 2023
Citation Information: J Clin Invest. 2023;133(8):e157937. https://doi.org/10.1172/JCI157937.
View: Text | PDF
Research Article Hepatology Immunology

In situ expansion and reprogramming of Kupffer cells elicit potent tumoricidal immunity against liver metastasis

  • Text
  • PDF
Abstract

Liver metastasis represents one of the most frequent malignant diseases with no effective treatment. Functional reprogramming of Kupffer cells (KCs), the largest population of hepatic macrophages, holds promise for treating liver cancer, but remains seldom exploited. Taking advantage of the superior capacity of KCs to capture circulating bacteria, we report that a single administration of attenuated Escherichia coli producing clustered regularly interspersed short palindromic repeats CasΦ (CRISPR/CasΦ) machinery enables efficient editing of genes of interest in KCs. Using intravital microscopy, we observed a failure of tumor control by KCs at the late stage of liver metastasis due to KC loss preferentially in the tumor core and periphery, resulting in inaccessibility of these highly phagocytic macrophages to cancer cells. Simultaneous disruption of MafB and c-Maf expression using the aforementioned engineered bacteria could overcome KC dysfunction and elicit remarkable curative effects against several types of metastatic liver cancer in mice. Mechanistically, bacterial treatment induced massive proliferation and functional reprogramming of KCs. These cells infiltrated into the tumor, dismantled macrometastases by nibbling cancer cells, and skewed toward proinflammatory macrophages to unleash antitumor T cell responses. These findings provide an immunotherapy strategy that could be applicable for treating liver metastasis and highlight the therapeutic potential of targeting tissue-resident macrophages in cancer.

Authors

Wei Liu, Xia Zhou, Qi Yao, Chen Chen, Qing Zhang, Keshuo Ding, Lu Li, Zhutian Zeng

×

Figure 5

Massive proliferation of KCs during BIL-CRISPR–mediated bacterial therapy.

Options: View larger image (or click on image) Download as PowerPoint
Massive proliferation of KCs during BIL-CRISPR–mediated bacterial therap...
(A) Intravital liver images of B16F10-ZsGreen tumor-bearing mice 7 days after bacterial treatment. Scale bar: 100 μm. (B) The area of ZsGreen+ tumors and (C) the number of KCs per FOV in A were quantified. A total of 12 randomly selected FOVs from 3 mice per group were analyzed. Mice at day 12 after intrasplenic B16 tumor injection were treated with E. coli–vector or E. coli–sgMafB/Maf and were harvested at day 19. (D) Representative flow cytometric plots of F4/80+TIM4+ tissue-resident KCs are shown. (E) Number of KCs in D. n = 4 mice per group. (F) Representative histogram of Ki67 expression in TIM4+F4/80+ KCs. (G) Normalized mRNA levels of Csf1, Csf2, and Il4 in tumor tissues versus tumor-distant liver tissues in bacteria-treated tumor-bearing mice. n = 4 mice per group. (H) Ki67-RFP mice with B16F10-ZsGreen liver metastasis were treated with E. coli–sgMafb/Maf i.v. Representative intravital liver images and enlarged pictures are shown at 2 days after bacterial treatment. Original magnification, zoomed images: × 2.8. (I) Ki67-RFP mice were i.p. injected with control IgG or CSF1R antibody at days 6, 8, and 10 after inoculation of B16F10-ZsGreen tumors, bacterial therapy was performed at day 7, and liver images were taken 4 days after bacterial treatment. (J) The number of TIM4+ KCs per FOV in I. A total of 20 FOVs from 3 mice per group were analyzed. Representative data from 2 independent experiments are shown. Data are represented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, unpaired Student’s t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts